Press Releases Year None2021202020192018201720162015201420132012 Nov 16 Regeneron Announces Investor Conference Presentations Nov 15 Regeneron Listed on Dow Jones Sustainability World Index for Third Consecutive Year Nov 12 Regeneron Announces $3 Billion Share Repurchase Program Nov 12 Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19 Nov 11 CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-19 Nov 8 New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19 Nov 4 Regeneron Presentations at ASH Highlight Expanding Clinical Research in Blood Cancers and Disorders Nov 4 Regeneron Reports Third Quarter 2021 Financial and Operating Results Oct 25 Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease Oct 22 Dupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this Disease Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Next page › Last page »